Farias José Wilson Mourão de, Furtado Flavia Siqueira, Guimarães Sergio Botelho, Silva Filho Antônio Ribeiro da, Vasconcelos Paulo Roberto Leitão de
Experimental Surgery Research Laboratory (LABCEX), Department of Surgery, Federal University of Ceara, Fortaleza-CE, Brazil.
Acta Cir Bras. 2011;26 Suppl 1:82-7. doi: 10.1590/s0102-86502011000700017.
To evaluate the effects of oral administration of GLN on the oxidative stress in women with breast cancer undergoing neoadjuvant FAC chemotherapy (5 fluouracil 500 mg/m²+Doxorubicin 50 mg/m²+Cyclophosphamide 500 mg/m² body surface area).
Twenty women (mean age: 51.7 years) with breast ductal carcinomas classified as T3 or T4 were included in the study, regardless of pre or post menopause status. Sachets containing glutamine 15g ("A") or milk protein 15g ("B") were prepared by a registered pharmacist. Allocation of patients was made by software program. Patients who received sachets labeled "A" were included in G1 group. The remaining patients, treated with the preparation labeled "B", were included in group G2. Sachets contents were blended in 150 ml of drinking water, and were given daily to each patient during the entire course of neoadjuvant chemotherapy. Peripheral blood samples were collected in the first day of each of the three cycles of chemotherapy before drug infusion. Tumor and normal breast samples were collected at the end of Patey´s surgical procedure. Samples were analysed for GSH and TBARS contents.
TBARS and GSH values were not different in breast healthy and tumor tissues nor blood when comparing control (G-2) and glutamine-treated (G-1) patients. Also, no significant differences were found in TBARS and GSH levels comparing different timepoints within the same group.
Oral GLN (15g/kg/day) offers no protection against systemic or local oxidative stress in women with breast Ca undergoing neoadjuvant chemotherapy (FAC).
评估口服谷氨酰胺（GLN）对接受新辅助FAC化疗（5-氟尿嘧啶500mg/m²+多柔比星50mg/m²+环磷酰胺500mg/m²体表面积）的乳腺癌女性氧化应激的影响。
本研究纳入了20名（平均年龄：51.7岁）导管型乳腺癌患者，肿瘤分期为T3或T4，无论其绝经前或绝经后状态。含15g谷氨酰胺的药包（“A”）或15g乳蛋白的药包（“B”）由注册药剂师制备。患者分组通过软件程序进行。接受标有“A”药包的患者纳入G1组。其余接受标有“B”制剂治疗的患者纳入G2组。将药包内容物混入150ml饮用水中，在新辅助化疗全过程中每天给予每位患者。在化疗三个周期中每个周期的第一天药物输注前采集外周血样本。在Patey手术结束时采集肿瘤及正常乳腺样本。分析样本中的谷胱甘肽（GSH）和丙二醛（TBARS）含量。
比较对照组（G-2）和谷氨酰胺治疗组（G-1）患者时，健康乳腺组织、肿瘤组织及血液中的TBARS和GSH值无差异。此外，在同一组内比较不同时间点时，TBARS和GSH水平也无显著差异。
口服GLN（15g/kg/天）对接受新辅助化疗（FAC）的乳腺癌女性的全身或局部氧化应激无保护作用。
